Key Points
- CEO Michael Davidson bought 10,000 NewAmsterdam Pharma shares at an average price of $22.65, investing $226,500 and increasing his direct ownership by 1.28% to 792,923 shares.
- NAMS opened at $21.16, near its 52-week low of $21.08 and well below its 50-day and 200-day moving averages. The company reported a quarterly EPS loss of $0.52, missing estimates, although revenue of $3.70 million exceeded expectations.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $49.73 price target versus the current share price. NewAmsterdam is developing obicetrapib, a cholesterol-lowering therapy for cardiometabolic disease.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) CEO Michael Davidson acquired 10,000 shares of the firm's stock in a transaction dated Monday, September 14th. The shares were purchased at an average price of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 792,923 shares in the company, valued at approximately $17,959,705.95. This trade represents a 1.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
NewAmsterdam Pharma Stock Performance
NAMS opened at $21.16 on Wednesday. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -9.80 and a beta of 0.09. The firm's fifty day moving average is $28.03 and its 200 day moving average is $30.99. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $21.08 and a fifty-two week high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The business had revenue of $3.70 million during the quarter, compared to analysts' expectations of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Royal Bank Of Canada cut their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Jefferies Financial Group reissued a "buy" rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. HC Wainwright restated a "buy" rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an "outperform" rating and a $58.00 price objective for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $49.73.
View Our Latest Analysis on NAMS
Institutional Investors Weigh In On NewAmsterdam Pharma
Several large investors have recently made changes to their positions in NAMS. AlphaCentric Advisors LLC boosted its holdings in NewAmsterdam Pharma by 6.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company's stock valued at $469,000 after acquiring an additional 925 shares during the period. KBC Group NV purchased a new stake in NewAmsterdam Pharma in the first quarter worth $37,000. AdvisorNet Financial Inc bought a new stake in shares of NewAmsterdam Pharma during the first quarter worth $82,000. Atle Fund Management AB boosted its stake in shares of NewAmsterdam Pharma by 1.8% during the fourth quarter. Atle Fund Management AB now owns 197,036 shares of the company's stock valued at $6,912,000 after purchasing an additional 3,411 shares during the period. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $140,000. 89.89% of the stock is owned by institutional investors.
NewAmsterdam Pharma Company Profile
(
Get Free Report)
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.
Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
